<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Kaspar Rufibach on Kaspar Rufibach</title>
    <link>https://numbersman77.netlify.com/</link>
    <description>Recent content in Kaspar Rufibach on Kaspar Rufibach</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <copyright>&amp;copy; 2019</copyright>
    <lastBuildDate>Tue, 01 Dec 2020 00:00:00 +0100</lastBuildDate>
    <atom:link href="/" rel="self" type="application/rss+xml" />
    
    <item>
      <title>Answering Old Questions with New Tools: Application of the ICH E9 Addendum in Oncology</title>
      <link>https://numbersman77.netlify.com/talk/invited/2020_10_demings_estimands/</link>
      <pubDate>Tue, 01 Dec 2020 00:00:00 +0100</pubDate>
      
      <guid>https://numbersman77.netlify.com/talk/invited/2020_10_demings_estimands/</guid>
      <description>&lt;p&gt;Course given together with Evgeny Degtyarev from Novartis.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>A deep dive into principal stratification and causal inference</title>
      <link>https://numbersman77.netlify.com/talk/invited/2020_8_effstat_podcast/</link>
      <pubDate>Tue, 17 Nov 2020 00:00:00 +0100</pubDate>
      
      <guid>https://numbersman77.netlify.com/talk/invited/2020_8_effstat_podcast/</guid>
      <description>&lt;p&gt;Principal stratification used to play a role only in observational research but at least since the addendum of the ICH E9 guideline, this approach to causal inference became a hot topic.&lt;/p&gt;

&lt;p&gt;We cover the following questions:&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;What is Principal Stratification?&lt;/li&gt;
&lt;li&gt;How would you describe principal stratification to a non-statistician?&lt;/li&gt;
&lt;li&gt;Where do you see the benefits of this estimand compared to the other typical strategies?&lt;/li&gt;
&lt;li&gt;Which critique points do are usually raised against this approach?&lt;/li&gt;
&lt;li&gt;How do you implement/calculate corresponding estimates for this estimand?&lt;/li&gt;
&lt;li&gt;What references would you recommend for further reading?&lt;/li&gt;
&lt;/ul&gt;
</description>
    </item>
    
    <item>
      <title>Estimands update: Summary of world-wide authority interaction</title>
      <link>https://numbersman77.netlify.com/talk/invited/2020_9_apf_estimands/</link>
      <pubDate>Tue, 17 Nov 2020 00:00:00 +0100</pubDate>
      
      <guid>https://numbersman77.netlify.com/talk/invited/2020_9_apf_estimands/</guid>
      <description>&lt;p&gt;Talk given together with Hannes Buchner from Staburo.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Conditional Power and Friends: The Why and How of (Un)planned, Unblinded Sample Size Recalculations in Confirmatory Trials</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2020_09_reestimation/</link>
      <pubDate>Tue, 13 Oct 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2020_09_reestimation/</guid>
      <description></description>
    </item>
    
    <item>
      <title>github repository and markdown file for SAVVY project: Survival analysis for AdVerse events with VarYing follow-up times</title>
      <link>https://numbersman77.netlify.com/software/savvy/</link>
      <pubDate>Sun, 06 Sep 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/software/savvy/</guid>
      <description>&lt;p&gt;The code in this github repository allows to compute the various estimators analyzed in the SAVVY project.&lt;/p&gt;

&lt;p&gt;&lt;a href=&#34;https://github.com/numbersman77/AEprobs&#34; target=&#34;_blank&#34;&gt;github repository&lt;/a&gt;&lt;br&gt;
&lt;a href=&#34;https://numbersman77.github.io/AEprobs/SAVVY_AEprobs.html&#34; target=&#34;_blank&#34;&gt;markdown&lt;/a&gt;&lt;br&gt;
&lt;a href=&#34;https://arxiv.org/abs/1912.00263&#34; target=&#34;_blank&#34;&gt;Paper: Statistical Analysis Plan of SAVVY project&lt;/a&gt;&lt;br&gt;
&lt;a href=&#34;https://arxiv.org/abs/2008.07883&#34; target=&#34;_blank&#34;&gt;Paper: Estimation of AE risks&lt;/a&gt;&lt;br&gt;
&lt;a href=&#34;https://arxiv.org/abs/2008.07881&#34; target=&#34;_blank&#34;&gt;Paper: Comparison of AE risk in a two-arm RCT&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Principal Stratum Strategy: Potential Role in Drug Development</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2020_08_principal_stratification/</link>
      <pubDate>Thu, 13 Aug 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2020_08_principal_stratification/</guid>
      <description></description>
    </item>
    
    <item>
      <title>github repository and markdown file for different analysis methods for principal stratum estimands motivated by the principal ignorability assumption</title>
      <link>https://numbersman77.netlify.com/software/principalstratification/</link>
      <pubDate>Thu, 13 Aug 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/software/principalstratification/</guid>
      <description>&lt;p&gt;The code in this github repository allows to reproduce all computations in the paper &amp;ldquo;Principal Stratum Strategy: Potential Role in Drug Development&amp;rdquo;.&lt;/p&gt;

&lt;p&gt;&lt;a href=&#34;https://github.com/oncoestimand/princ_strat_drug_dev&#34; target=&#34;_blank&#34;&gt;github repository&lt;/a&gt;&lt;br&gt;
&lt;a href=&#34;https://oncoestimand.github.io/princ_strat_drug_dev/princ_strat_example.html&#34; target=&#34;_blank&#34;&gt;markdown&lt;/a&gt;&lt;br&gt;
&lt;a href=&#34;https://arxiv.org/abs/2008.05406&#34; target=&#34;_blank&#34;&gt;paper&lt;/a&gt;&lt;br&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) - comparison of adverse event risks in randomized controlled trials</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2020_07_savvy_2sample/</link>
      <pubDate>Wed, 12 Aug 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2020_07_savvy_2sample/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) - estimation of adverse event risks</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2020_06_savvy_1sample/</link>
      <pubDate>Tue, 11 Aug 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2020_06_savvy_1sample/</guid>
      <description></description>
    </item>
    
    <item>
      <title>A review of Bayesian perspectives on sample size derivation for confirmatory trials</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2020_05_bayes_samplesize/</link>
      <pubDate>Mon, 29 Jun 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2020_05_bayes_samplesize/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Estimands for Overall Survival in Clinical Trials with Treatment Switching</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2020_04_estimand_switching/</link>
      <pubDate>Sat, 27 Jun 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2020_04_estimand_switching/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Estimands in Hematology Trials</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2020_03_heme_estimand/</link>
      <pubDate>Thu, 25 Jun 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2020_03_heme_estimand/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic study</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2020_02_savvy_sap/</link>
      <pubDate>Sat, 20 Jun 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2020_02_savvy_sap/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Assessing the impact of COVID-19 on the objective and analysis of oncology clinical trials - application of the estimand framework</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2020_01_estimand_covid/</link>
      <pubDate>Sun, 10 May 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2020_01_estimand_covid/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Integrating Phase 2 into Phase 3 based on an Intermediate Endpoint While Accounting for a Cure Proportion</title>
      <link>https://numbersman77.netlify.com/publication/stats_articles/2019_04_mirros/</link>
      <pubDate>Sat, 01 Feb 2020 00:00:00 +0000</pubDate>
      
      <guid>https://numbersman77.netlify.com/publication/stats_articles/2019_04_mirros/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
